BioStock has published an in-depth article on Ultimovacs

“Cancer’s heavy burden on society has created a strong demand for new innovative therapeutic solutions. Over the last decade, immunotherapy has emerged as one of the most promising fields within oncology, and several biotech and pharma companies are exploiting this promise by developing immunotherapy-based drugs. Norwegian Ultimovacs is one of them. Their immunotherapy technology may work as a vaccine for treating all forms of cancer. BioStock takes an in-depth look at the company.”

Read the full article from Biostock here: